Outlook Therapeutics, Inc. (OTLK) SEC Filings

Outlook Therapeutics, Inc. (OTLK) reports that its Chief Financial Officer, Kevin Michael Lundquist, has filed an initial statement of beneficial ownership on Form 3. The filing does not list any equity holdings, derivative positions, or transactions in Outlook Therapeutics securities by the reporting person.

Outlook Therapeutics, Inc. (OTLK) announced a planned chief financial officer transition. Lawrence A. Kenyon will cease serving as Chief Financial Officer, Treasurer, Corporate Secretary, principal financial officer and principal accounting officer effective September 1, 2026, and will remain in a non-executive role through September 30, 2026, after which he will also leave the Board and the Board size will be reduced to eight directors. The company states his departure is not due to any disagreement on accounting, financial reporting, operations, policies or practices.

The Board appointed Kevin Lundquist as Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer effective on the transition date. His employment agreement provides a $450,000 initial base salary, target bonus equal to 50% of base salary, and an option to purchase 500,000 shares, vesting over four years. Lundquist is entitled to specified cash severance, benefits continuation and, in a change in control context, full vesting of unvested time-vesting equity upon a qualifying termination. Kenyon’s separation agreement provides lump-sum cash severance based on 12 or 18 months of base salary plus additional amounts, full option vesting, and COBRA benefits, with enhanced terms if a change in control occurs within two months after his separation.

Outlook Therapeutics, Inc. (OTLK) is reported as the issuer of common stock held by institutional investors CVI Investments, Inc. and Heights Capital Management, Inc., which together are treated as "Reporting Persons." They report beneficial ownership of 24,713,908 shares of Outlook Therapeutics common stock, including 20,000,000 shares of common stock and additional shares issuable upon exercise of warrants, subject to a 9.99% beneficial ownership cap that limits warrant exercisability. Based on an indicated 242,672,554 shares outstanding as of the completion of a referenced offering, the Reporting Persons state that their holdings represent 9.9% of the outstanding common stock. Voting and dispositive power over these shares is shared, with Heights Capital Management acting as investment manager to CVI Investments and potentially exercising such powers, while both entities disclaim beneficial ownership beyond their pecuniary interest.

Outlook Therapeutics, Inc. (OTLK) reported continued operating losses while advancing LYTENAVA, its ophthalmic bevacizumab, toward broader commercialization. For the nine months ended June 30, 2026, net loss was $47.8 million versus $49.1 million a year earlier, with revenues, net of gross‑to‑net adjustments, of $(1.1) million compared with $1.5 million, driven largely by reserve changes and low early European sales. Operating cash outflow was $43.8 million, and cash and cash equivalents were $11.2 million at June 30, 2026.

Total assets were $26.2 million against $36.6 million of liabilities, leaving a stockholders’ deficit of $10.4 million. Management disclosed substantial doubt about the ability to continue as a going concern, citing recurring losses, a working capital deficit, and outstanding obligations including an unsecured promissory note to Atlas Sciences with $20.3 million of principal, accrued interest and exit fees outstanding and maturing in June 2027. The company has been funding operations primarily through equity, warrant exercises, and debt, including multiple 2026 offerings and a new at‑the‑market program.

Strategically, Outlook expanded its intellectual property portfolio and continued commercial rollout of LYTENAVA in Europe. Critically, in July 2026, after quarter‑end, the FDA approved LYTENAVA (bevacizumab‑vikg) as the first FDA‑approved ophthalmic bevacizumab for wet AMD in the United States, conferring 12 years of U.S. regulatory exclusivity. The company is preparing a U.S. launch before December 31, 2026 and subsequently raised approximately $51.1 million in an August 2026 follow‑on equity and warrant offering to help fund commercialization and general corporate purposes.

Outlook Therapeutics, Inc. director and Chief Executive Officer Robert Charles Jahr purchased 151,515 shares of common stock and 151,515 accompanying warrants on August 14, 2026 in an underwritten public offering at a combined public offering price of $0.99 per share and warrant. The warrants are exercisable immediately at $1.10 per share and expire on August 14, 2031. Following these transactions, Jahr holds 151,515 common shares and 151,515 warrants directly.

Outlook Therapeutics, Inc. reported that GMS Ventures & Investments and its controlling person, Ghiath M. Sukhtian, updated their beneficial ownership following an August 2026 underwritten public offering. GMS Ventures now beneficially owns a total of 42,631,142 shares of common stock, including 18,013,822 warrants, representing approximately 16.4% of Outlook Therapeutics’ outstanding common stock calculated under Rule 13d-3.

The change stems from the company’s sale of 55,555,556 shares and accompanying warrants in the August 2026 offering. GMS Ventures purchased 2,525,252 shares and accompanying warrants for an aggregate price of approximately $2.5 million at $0.99 per share-plus-warrant unit, funded by its working capital and capital contributions. The new warrants held by GMS Ventures are immediately exercisable at $1.10 per share and expire five years after issuance. The ownership percentages are based on 242,672,554 shares outstanding after the offering plus the warrant shares.

Outlook Therapeutics, Inc. insider GMS Ventures & Investments, associated with director and 10% owner Ghiath M. Sukhtian, participated in an underwritten public offering on August 12, 2026. GMS Ventures purchased 2,525,252 shares of common stock at $0.99 per share and received accompanying warrants to purchase 2,525,252 shares of common stock at an exercise price of $1.10 per share. The warrants were issued for $0.00 as part of the combined public offering price, are exercisable immediately, and expire on August 14, 2031 subject to a beneficial ownership limitation. Following the stock purchase, GMS Ventures held 24,617,320 shares of Outlook Therapeutics common stock indirectly reported for Sukhtian, with both reporting persons disclaiming beneficial ownership beyond their pecuniary interest.

Outlook Therapeutics, Inc. director and Chief Financial Officer Lawrence A. Kenyon reported open-market-style purchases tied to an underwritten public offering on August 14, 2026. He acquired 101,010 shares of common stock plus accompanying warrants to purchase another 101,010 shares, for a combined public offering price of $0.99 per share and warrant. The warrants are immediately exercisable at $1.10 per share and expire on August 14, 2031. Following the stock purchase, he held 106,956 common shares directly.